FDA identifies 20 drugs that need approved risk eval, strategy

Share this article:
FDA identified 20 Rx drugs and biologics that must have an approved risk evaluation and mitigation strategy, including GlaxoSmith-Kline's Lotronex, Novartis' Clozaril, Cephalon's Actiq, Hoffmann-LaRoche's Accutane, Celgene's Revlimid and Thalomid, Danco's Mifeprex and Biogen Idec's Tysabri.
Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.